The U.S. Food and Drug Administration granted expanded approval to Emergent BioSolutions' smallpox vaccine for use in people at high risk of mpox infection, sending the drugmaker's shares 5% higher on Friday.

As a new deadly strain of mpox continues its global spread, Emergent BioSoultion's smallpox vaccine ACAM2000 has officially joined the ranks of FDA-approved defense measures against the virus.&nbsp | With the nod,

The Emergent vaccine is now the second one to win FDA approval after one developed by Danish biotech Bavarian Nordic.

The U.S. FDA has widened approval for Emergent BioSolutions' smallpox vaccine, ACAM2000, to include those at high risk of mpox infection. Despite limitations, this approval elevates the vaccine as a crucial measure against the outbreak.

Emergent BioSolutions (EBS) shares surge as FDA approves expanded use of ACAM2000 smallpox vaccine for high-risk mpox infection, amid global outbreak.

In a bid to deal with mpox infection, the US Food and Drug Administration approved expanded use of Emergent BioSolutions' EBS.N ACAM2000 smallpox vaccine to include people at high risk for

The U.S. FDA has expanded approval for Emergent BioSolutions' smallpox vaccine, ACAM2000, for high-risk mpox individuals, boosting the company's shares by 20%. Despite its restrictions for people with weakened immune systems,

The U.S. Food and Drug Administration granted expanded approval to Emergent BioSolutions' smallpox vaccine for use in people at high risk of mpox infection, sending the drugmaker's shares surging 15% before the bell on Friday.

The FDA approved a supplemental application to expand Emergent BioSolutions' existing smallpox vaccine to include Mpox.